MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December..

加利福尼亚州门洛帕克（商业新闻短讯）--生物制药公司AN2 Therapeutics，Inc.（纳斯达克：ANTX）今天宣布，公司管理层将参加12月即将举行的两次投资者会议。AN2 Therapeutics，Inc.（纳斯达克：ANTX）是一家专注于发现和开发源自其硼化学平台的新型小分子治疗剂的生物制药公司。。

Details of the events are as follows:

活动详情如下：

7th Annual Evercore HealthCONx Conference, December 3-5, 2024

Eric Easom, Co-Founder, Chairman, President and CEO, will provide a corporate overview on Wednesday, December 4 at 8:20am ET

联合创始人、董事长、总裁兼首席执行官埃里克·伊瑟姆将于美国东部时间12月4日星期三上午8:20提供公司概况

Oppenheimer’s Movers in Rare Disease Summit, December 12, 2024

2024年12月12日，奥本海默罕见病峰会的推动者

Members of management will be available for 1X1 meetings on Thursday, December 12, 2024

管理层成员将于2024年12月12日（星期四）参加1X1会议

A webcast of the Evercore HealthCONx Conference presentation can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.

Evercore HealthCONx会议演示文稿的网络广播可在AN2 Therapeutics网站的投资者部分访问，网址为www.an2therapeutics.com。演示文稿后至少30天内将提供存档的重播。

About AN2 Therapeutics, Inc.

关于AN2 Therapeutics，Inc。

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, NTM, and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

AN2 Therapeutics，Inc.是一家生物制药公司，专注于发现和开发源自其硼化学平台的新型小分子疗法。AN2拥有一条用于恰加斯病、NTM和类鼻疽的硼基化合物开发管道，以及专注于传染病和肿瘤学目标的早期项目。

For more information, please visit our website at www.an2therapeutics.com..

有关更多信息，请访问我们的网站www.an2therapeutics.com。。